文献速递淋巴瘤

瑞基奥仑赛(CD19 CAR-T)治疗中国成人复发/难治套细胞淋巴瘤的2期研究

Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.
PubMed 文献 · Blood Adv · 2026-01-01

这项2期、开放标签、单臂、多中心研究纳入70例经多线治疗的复发/难治套细胞淋巴瘤(MCL)中国患者,59例接受单次100×10^6 CAR阳性T细胞输注;3个月客观缓解率为71.19%,完全缓解率为59.32%;中位随访13.3个月,中位缓解持续时间18.1个月、无进展生存期15.5个月、总生存期19.5个月;未报告致命事件。

要点

  • 3个月客观缓解率为71.19%(95%CI 57.92-82.24),完全缓解率为59.32%(95%CI 45.75-71.93)。
  • 中位随访13.3个月(95%CI 9.04-18.69),中位缓解持续时间18.1个月、无进展生存期15.5个月、总生存期19.5个月。
  • 严重细胞因子释放综合征和神经毒性各发生于6.8%的患者,均完全缓解,未报告致命事件。

核心结论

  • 瑞基奥仑赛在中国复发/难治套细胞淋巴瘤患者中显示出高缓解率、持久缓解和可控的安全性。

研究设计与样本

  • 2期、开放标签、单臂、多中心研究,纳入70例既往接受1至9线治疗(包括蒽环类或苯达莫司汀化疗、抗CD20抗体和布鲁顿酪氨酸激酶抑制剂)的复发/难治套细胞淋巴瘤中国患者。
  • 其中59例在白细胞分离后接受单次100×10^6 CAR阳性T细胞输注。
  • 主要终点为输注后3个月按Lugano 2014标准评估的客观缓解率。
  • 次要终点包括缓解持续时间、无进展生存期、总生存期和安全性。

主要发现

  • 3个月客观缓解率为71.19%(95%CI 57.92-82.24),完全缓解率为59.32%(95%CI 45.75-71.93)。
  • 中位随访13.3个月(95%CI 9.04-18.69),中位缓解持续时间为18.1个月、无进展生存期为15.5个月、总生存期为19.5个月。
  • 3级及以上治疗中出现的不良事件常见,包括中性粒细胞减少(76.3%)、白细胞减少(69.5%)和淋巴细胞减少(47.5%)。
  • 严重细胞因子释放综合征和神经毒性各发生于6.8%的患者,所有病例均完全缓解。
  • 未报告致命事件。

关键数值与推荐

  • 客观缓解率71.19%(95%CI 57.92-82.24),完全缓解率59.32%(95%CI 45.75-71.93),评估时间为输注后3个月。
  • 中位随访13.3个月(95%CI 9.04-18.69),中位缓解持续时间18.1个月、无进展生存期15.5个月、总生存期19.5个月。
  • 3级及以上中性粒细胞减少76.3%、白细胞减少69.5%、淋巴细胞减少47.5%;严重细胞因子释放综合征和神经毒性各6.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relmacabtagene autoleucel (relma-cel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, is approved in China for relapsed/refractory (R/R) large B-cell lymphoma and follicular lymphoma. This phase 2, open-label, single-arm, multicenter study evaluated its efficacy and safety in Chinese patients with heavily pretreated R/R mantle cell lymphoma (MCL). A total of 70 patients with R/R MCL who had received 1 to 9 previous therapies (including anthracycline or bendamustine chemotherapy, anti-CD20 antibodies, and Bruton tyrosine kinase [BTK] inhibitors) were enrolled. Of these, 59 received a single infusion of 100 × 106 CAR-positive T cells following leukapheresis. The primary end point was the objective response rate (ORR) at 3 months after infusion, assessed using the Lugano 2014 criteria. Secondary end points included the duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. At 3 months, the ORR was 71.19% (95% confidence interval [CI], 57.92-82.24) with a complete response rate of 59.32% (95% CI, 45.75-71.93). After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median DOR was 18.1 months, PFS was 15.5 months, and OS was 19.5 months. Grade 3 or higher treatment-emergent adverse events were common, including neutropenia (76.3%), leukopenia (69.5%), and lymphopenia (47.5%). Severe cytokine release syndrome and neurotoxicity occurred in 6.8% of patients each, and all cases resolved fully. No fatal events were reported. These findings demonstrate that relma-cel offers high response rates, durable remissions, and manageable safety in Chinese patients with R/R MCL. This trial was registered at www.clinicaltrials.gov as #NCT04718883.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Xie Y, Zhou KS, Li LF, et al. Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. Blood Adv. 2026. PMID: 40811825. doi:10.1182/bloodadvances.2024015763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。